Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Shilpa Medicare gains 3.5% after receiving FDA approval for an injection

1 January, 2019 4:22 AM
110 0
Shilpa Medicare gains 3.5% after receiving FDA approval for an injection

Shilpa Medicare's Irinotecan injection is used to treat patients with metastatic cancer of the colon or rectum.

Shares of Shilpa Medicare rose over 3.5 percent in early trade on January 1 after the company received FDA approval for its Irinotecan injection.

The stock gained as much as 4.5 percent on the BSE, quoting at Rs 401.3.

The US Food and Drug Administration (USFDA) gave the company approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials.

Irinotecan injection is used to treat patients with metastatic cancer of the colon or rectum.

Source: moneycontrol.com

Share in social networks:

Comments - 0